FOR IMMEDIATE RELEASE
CONTACT: Kirsten Spittel, 202-303-3104, email@example.com
Update (03/09/2017): Fiscal Year 2017 Defense Funding Bill Passes House
Washington, D.C. – Fresh off storming Capitol Hill, prostate cancer advocates from 35 states learned of the hard-fought win as they packed their bags for home this morning – The Department of Defense’s Prostate Cancer Research Program earned a $10M increase.
The news comes as the House Appropriations Committee introduced the final version of the fiscal year 2017 Defense Appropriations bill, which includes $90 million for the Department of Defense’s Prostate Cancer Research Program (PCRP). This is the first increase to the program in over a decade. Representative Peter King (R-NY), Rep. Sanford Bishop (D-GA), Senator Mike Crapo (R-ID), and Sen. Robert Menendez (D-NJ) spearheaded the effort to support PCRP funding, securing signatures from over 100 House and Senate members on letters to the appropriations committee.
“The power of passionate patients and families impacted by prostate cancer speaking with one voice makes all the difference,” Jamie Bearse, CEO of ZERO – The End of Prostate Cancer, said. “It’s a tremendous win for our advocates and we’re incredibly thankful to House Appropriations Committee members, especially Chairman Rodney Frelinghuysen.”
As part of the ZERO Prostate Cancer Summit on Wednesday, more than 150 advocates from across the country met with elected officials about increasing prostate cancer research for the 2018 fiscal year budget when the news started to break about this year’s budget.
The Department of Defense’s medical research programs are a proven business model and an epicenter for groundbreaking research in many medical fields including prostate cancer. The DOD program hosts patients as part of a peer-review model in choosing which bright ideas to fund. Specifically, the Prostate Cancer Research Program has awarded grants that have led to three new treatments for the disease in recent years and a genetic diagnosis profile to determine aggressive disease.
The bill will be considered on the House floor next week. This conference report is the result of many months of negotiation between the House and Senate. Once the bill passes the House, it will move to the Senate for final votes. This would be a major victory for prostate cancer advocates: the largest increase in funding for the PCRP since 2001.
About ZERO — The End of Prostate Cancer
ZERO — The End of Prostate Cancer is the leading national nonprofit with the mission to end prostate cancer. ZERO advances research, improves the lives of men and families, and inspires action. We’re building Generation ZERO, the first generation of men free from prostate cancer, through our national run/walk series, education and patient support programs, and grassroots advocacy. ZERO is a 501(c)(3) philanthropic organization recognized with four out of four stars by Charity Navigator, accredited by the Better Business Bureau, with regional chapters across the country. We dedicate 85 cents of every dollar to research and programs. For more information, visit www.zerocancer.org.